Current Perspectives on Gene Transfer for X-linked Severe Combined Immunodeficiency Disease (X-SCID)
  On December 4-5, 2002, February 10, 2003, March 15, 2005, March 14, 2007 and March 11, 2008, the RAC reviewed the clinical and molecular data concerning three adverse events that occurred in a French study involving engraftment of a CD34+ hematopoietic stem cell enriched, cell population transduced with a retroviral vector encoding the common gamma chain (γ) transmembrane protein subunit shared by receptors for Interleukins 2, 4, 7, 9, 15 and 21. The leukemias appear to share the common causative mechanism of insertional mutagenesis at or near oncogenes. The major goal of the symposia was to increase awareness in the scientific community and the public by providing comprehensive updates of:  
   The current US and international trials using gene transfer for SCID, including recently emerging safety data  
   Retrovirus integration and insertional mutagenesis research  
   The use of bone marrow/stem cell transplantation as treatment for SCID  
  The RAC developed recommendations for the use of gene transfer for X-SCID and other indications using retroviral vectors.  
 

  March 11, 2008  
  Agenda and Slides   
  Webcast   
 

  March 14, 2007  
  Agenda   
  Webcasts  and Minutes   
  Slides  
 

  March 15, 2005  
  Agenda   
  Slides  
  Summary   
  References  
  Conclusions and Recommendations  of the RAC Gene Transfer Safety Symposium: Current Perspectives on Gene Transfer for X-SCID (March 15, 2005)  
 

  February 10, 2003  
  Webcast
  Conclusions and Recommendations  of the RAC Regarding Adverse Events in a Gene Transfer Trial Studying X-linked SCID (March 20, 2003)  
 

  December 4-5, 2002  
  Minutes   
  Slides- December 4, 2002  
  Slides - December 5, 2002  
 


Top of Page
 


6705 Rockledge Drive, Suite 750, MSC 7985
Bethesda, MD 20892-7985 (For all non-USPS mail, please use ZIP code 20817)
Phone: 301-496-9838, Fax: 301-496-9839
E-mail OBA at oba@od.nih.gov

RDNA125